Literature DB >> 31033999

Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom.

Lucy T Perry1, Alice Bhasale1, Alice Fabbri1, Joel Lexchin2, Lorri Puil3, Maisah Joarder1, Barbara Mintzes1.   

Abstract

Year:  2019        PMID： 31033999      PMCID： PMC6583834          DOI： 10.1001/jamainternmed.2019.0294

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  4 in total

Review 1.  Communication of medical product risk: how effective is effective enough?

Authors:  Stephen A Goldman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  A call for international harmonization in therapeutic risk management.

Authors:  Ceri Hirst; Suzanne Cook; Wanju Dai; Susana Perez-Gutthann; Elizabeth Andrews
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-12       Impact factor: 2.890

Review 3.  Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.

Authors:  Stacie B Dusetzina; Ashley S Higashi; E Ray Dorsey; Rena Conti; Haiden A Huskamp; Shu Zhu; Craig F Garfield; G Caleb Alexander
Journal:  Med Care       Date:  2012-06       Impact factor: 2.983

4.  Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.

Authors:  Jean-David Zeitoun; Jérémie H Lefèvre; Nicholas Downing; Henri Bergeron; Joseph S Ross
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240
  4 in total
  6 in total

1.  US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS).

Authors:  Thomas J Moore; Richard L Morrow; Colin R Dormuth; Barbara Mintzes
Journal:  Pharmaceut Med       Date:  2020-04

2.  Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab.

Authors:  Alice Fabbri; Mary O'Keeffe; Ray Moynihan; Mathias Møllebaek; Annim Mohammad; Alice Bhasale; Lorri Puil; Barbara Mintzes
Journal:  Br J Clin Pharmacol       Date:  2020-03-20       Impact factor: 4.335

3.  Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies.

Authors:  Ashleigh Hooimeyer; Alice Bhasale; Lucy Perry; Alice Fabbri; Annim Mohammad; Eliza McEwin; Barbara Mintzes
Journal:  Pharmacol Res Perspect       Date:  2020-12

4.  Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study.

Authors:  Meera M Dhodapkar; Xiaoting Shi; Reshma Ramachandran; Evan M Chen; Joshua D Wallach; Joseph S Ross
Journal:  BMJ       Date:  2022-10-05

5.  Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.

Authors:  Anna Kemp-Casey; Barbara Mintzes; Richard L Morrow; Colin R Dormuth; Patrick C Souverein; Elizabeth E Roughead
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-07-27       Impact factor: 2.732

6.  Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature.

Authors:  Daniele Sartori; Jeffrey K Aronson; Igho J Onakpoya
Journal:  Syst Rev       Date:  2020-08-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.